Catch up on a variety of FDA news in radiology from the past week.
|Articles|February 14, 1996
GE names new MRI executives
GE Medical Systems of Milwaukee has made several changes to theexecutive line-up of its MRI division. Morry Blumenfeld has beennamed general manager of advanced MR development. Blumenfeld willoversee GE's MR-guided surgery effort and will manage
Advertisement
GE Medical Systems of Milwaukee has made several changes to theexecutive line-up of its MRI division. Morry Blumenfeld has beennamed general manager of advanced MR development. Blumenfeld willoversee GE's MR-guided surgery effort and will manage programson special-purpose MRI systems, new magnet configurations, andnew clinical applications. Blumenfeld previously oversaw GE'sdevelopment of its 0.5-tesla open interventional MRI scanner.
In addition to Blumenfeld's appointment, GE has named YoshiakiFujimori as global general manager of GE's MRI business, replacingNobuhiko Ito. Fujimori previously headed GE's global CT business.
In other GE news, the vendor said that it has signed an agreementwith Opgal Optronic Industries of Karmiel, Israel, that givesGE distribution and service rights to a new line of cardiac imagingequipment. The products will be used by cardiac surgeons to makesure that grafted blood vessels used in bypass operations arefunctioning properly before open heart surgery is performed.
Advertisement
Related to this article
Catch up on the top radiology content of the past week.
Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.
Incorporating structural MRI to improve PET imaging resolution, the MICSI-PET software also offers automated Centiloid quantification from amyloid PET scans.
Emerging research demonstrates the increasing stability of attenuation on clinically relevant VMIs with photon-counting CT and a redefined role of kV that may have implications for longitudinal quantitative CT.
For patients with intermediate-risk prostate cancer, those with lower apparent diffusion coefficient (ADC) values on pre-treatment DWI MRI had a fourfold higher prevalence of distant metastasis in a study with a 10.3-year median follow-up.
In the second of a two-part podcast episode, Lauren Nicola, MD, Christoph Wald, MD, PhD, MBA, and Peter Shen discuss challenges with evaluating value and ROI for AI software, the physician time required to do so, and possible solutions to facilitate improved clarity and consistency with AI reimbursement.
In the latest episode of her “Breast Imaging in Focus” series, Manisha Bahl, MD, MPH, FSBI, offer pertinent takeaways for breast radiologists from recently issued guidelines for addressing proliferative breast lesions with atypia and lobular carcinoma in situ (LCIS).
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Radiology Roundup of FDA News: September 13 — September 19
2
Does kV Still Matter in Photon-Counting CT?
3
Foundation Model-Based Chest X-Ray AI Software Gets FDA Nod
4
FDA Clears Software That Combines MRI Enhancement of PET Imaging with Automated Quantification of Amyloid and Tau PET
5